The PAH Platform for Deep Phenotyping in Korean Subjects
NCT03933579 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2019-05-01
Summary
A total of 16 regional hospitals will be registering clinical data and biological specimens of idiopathic pulmonary arterial hypertension (IPAH)/heritable pulmonary arterial hypertension (HPAH) patients across Korea. The diagnosis of pulmonary arterial hypertension(PAH) will be based on right heart catheterization, where PAH caused by etiology other than HPAH or IPAH will be excluded. All clinical data will be stored to a government-based online database. Each participating hospitals will be collecting whole blood from each patient, through which DNA, RNA, serum, plasma, and peripheral blood mononuclear cells will be extracted from the buffy coat layer for further multi-omics analysis.
Conditions
- Pulmonary Arterial Hypertension
- Deep Phenotyping
- Idiopathic Pulmonary Arterial Hypertension
- Heritable Pulmonary Arterial Hypertension
Interventions
- DIAGNOSTIC_TEST
-
Deep phenotyping
Each participating hospitals will be collecting whole blood from each patient, through which DNA, RNA, serum, plasma, and peripheral blood mononuclear cells will be extracted from the buffy coat layer for further multi-omics analysis.
Sponsors & Collaborators
-
Sejong General Hospital
collaborator OTHER -
Chonnam National University Hospital
collaborator OTHER -
Keimyung University Dongsan Medical Center
collaborator OTHER -
Saint Vincent's Hospital, Korea
collaborator OTHER -
Seoul National University
collaborator OTHER -
Chungnam National University Hospital
collaborator OTHER -
Wonju Severance Christian Hospital
collaborator OTHER -
Asan Medical Center
collaborator OTHER -
Wonkwang University Hospital
collaborator OTHER -
Chungbuk National University Hospital
collaborator OTHER -
Samsung Medical Center
collaborator OTHER -
Severance Hospital
collaborator OTHER -
The Catholic University of Korea
collaborator OTHER -
Seoul National University Bundang Hospital
collaborator OTHER -
Pusan National University Hospital
collaborator OTHER -
Chonbuk National University Hospital
collaborator OTHER -
Pusan National University Yangsan Hospital
collaborator OTHER -
Gachon University Gil Medical Center
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-03-01
- Primary Completion
- 2020-12-31
- Completion
- 2020-12-31
Countries
- South Korea
Study Locations
More Related Trials
-
Pharmacogenomics in Pulmonary Arterial Hypertension
NCT00593905 ·Status: WITHDRAWN
-
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
NCT06753981 ·Status: RECRUITING
-
129 Xenon Imaging in Patients Treated With Sotatercept
NCT06351345 ·Status: RECRUITING ·Phase: PHASE2
-
Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH
NCT03841344 ·Status: UNKNOWN ·Phase: NA
-
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467 ·Status: RECRUITING
-
Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
NCT02304198 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)
NCT06084559 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Pulmonary Hypertension--Mechanisms and Family Registry
NCT00005357 ·Status: COMPLETED
-
Endothelial Cell Activation and Total Pulmonary Resistance in PAH
NCT06035861 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
NCT04955990 ·Status: TERMINATED ·Phase: PHASE4
-
Hormonal, Metabolic, and Signaling Interactions in PAH
NCT01884051 ·Status: RECRUITING
-
Assessing the Utility of Submaximal CPET in Treatment Management of PAH
NCT05977933 ·Status: NOT_YET_RECRUITING
-
Acute Excposure of High Altitude on ECG and Non-invasive Blood Pressure.
NCT03593083 ·Status: COMPLETED ·Phase: NA
-
Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients
NCT02551653 ·Status: COMPLETED ·Phase: PHASE1
-
Acute Exposure of High Altitude on Cognitive Function
NCT03637192 ·Status: COMPLETED ·Phase: NA
-
Novel Index (PIMR) in PAH
NCT05812976 ·Status: COMPLETED
-
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
NCT05372263 ·Status: RECRUITING
-
Efficacy of Triple-Combination Therapy in Severe PAH-CHD
NCT06196801 ·Status: ACTIVE_NOT_RECRUITING
-
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
NCT00454558 ·Status: COMPLETED ·Phase: PHASE2
-
Discovering Clinical Study Experiences of Patients With Pulmonary Hypertension
NCT05918458 ·Status: NOT_YET_RECRUITING
-
Acute Exposure of High Altitude on Cardiac Output
NCT03637218 ·Status: COMPLETED ·Phase: NA
-
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
NCT02191137 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT07073820 ·Status: RECRUITING ·Phase: PHASE2
-
Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs
NCT03863990 ·Status: COMPLETED
-
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421 ·Status: RECRUITING